Non-mutational resistance to KRAS inhibition can be driven by a variety of factors, such as the upstream activation of the pathway by the alleviation of feedback, the reactivation of the pathway by the activation of a downstream member, the activation of alternative growth pathways, EMT, alterations in the tumor microenvironment, drug efflux pump activity, and others. The gene discussed is KRAS; the disease is neoplasm.